BIOCON2022-10-012022-12-31 BIOCON2022-10-012022-12-31 BIOCON2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member BIOCON2022-10-012022-12-31in-bse-fin:OneOperatingExpenses02Member BIOCON2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member BIOCON2022-10-012022-12-31in-bse-fin:FourOperatingExpenses02Member BIOCON2022-12-31 BIOCON2022-10-012022-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2022-10-012022-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2022-10-012022-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member BIOCON2022-10-012022-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532523 BIOCON NOTLISTED Biocon Limited Equity 2022-04-01 2023-03-31 2023-02-14 2023-01-06 INR Millions Third quarter 15:30:00 18:50:00 2023-02-14 2023-02-14 Not applicable Single segment Pharmaceutical 2022-10-01 2022-12-31 Unaudited Standalone 5550000000.00 599000000.00 6149000000.00 2864000000.00 6000000.00 -224000000.00 1115000000.00 214000000.00 291000000.00 1418000000.00 5684000000.00 465000000.00 0.00 465000000.00 113000000.00 0.00 113000000.00 0.00 352000000.00 0.00 0.00 0.00 0.00 352000000.00 28000000.00 380000000.00 0.00 0.00 6003000000.00 5 0.29 0.29 0.00 0.00 0.29 0.29 1. The unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2022 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 14, 2023. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include the financial results of the parent company Biocon Limited and the financial results of the following subsidiaries: i. Syngene International Limited (‘Syngene’) ii. Biocon Biologics Limited (“BBL”) (formerly known as ‘Biocon Biologics India Limited’) iii. Biocon Pharma Limited (“BPL”) iv. Biocon Academy v. Biocon SA vi. Biocon SDN. BHD vii. Biocon FZ LLC viii. Biocon Biologics UK Limited (formerly known as ‘Biocon Biologics Limited’) ix. Biocon Pharma Inc. x. Biocon Biologics Healthcare Malaysia SDN. BHD (formerly known as ‘Biocon Healthcare SDN. BHD’) xi. Biocon Pharma Ireland Limited xii. Biocon Pharma UK Limited xiii. Biocon Biosphere Limited xiv. Biocon Biologics Inc. xv. Biocon Biologics Do Brasil Ltda xvi. Biocon Biologics FZ-LLC xvii. Biocon Pharma Malta Limited xviii. Biocon Pharma Malta I Limited xix. Biofusion Therapeutics Limited xx. Syngene USA Inc. xxi. Syngene Manufacturing Solutions Limited xxii. Syngene Scientific Solutions Limited xxiii. Biosimilar Collaborations Ireland Limited xxiv. Biosimilars Newco Limited Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene International Limited Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associates i.e. Iatrica Inc., Bicara Therapeutics Inc. (“Bicara”), under the equity method. Single segment 2022-04-01 2022-12-31 Unaudited Standalone 14862000000.00 2074000000.00 16936000000.00 7160000000.00 21000000.00 -201000000.00 3262000000.00 215000000.00 875000000.00 3945000000.00 15277000000.00 1659000000.00 10092000000.00 11751000000.00 1375000000.00 0.00 1375000000.00 0.00 10376000000.00 0.00 0.00 0.00 0.00 10376000000.00 -13000000.00 10363000000.00 0.00 0.00 6003000000.00 5 8.70 8.68 0.00 0.00 8.70 8.68 Less: Recovery of cost from co-development partners (net) 0.00 Other Expenses 1418000000.00 Less: Recovery of cost from co-development partners (net) -14000000.00 Other Expenses 3959000000.00 Items that will not be reclassified to profit and loss 7000000.00 Items that will not be reclassified to profit and loss -5000000.00 7000000.00 -5000000.00 1000000.00 -2000000.00 Items that willm be reclassified to profit or loss 30000000.00 Items that willm be reclassified to profit or loss -16000000.00 30000000.00 -16000000.00 8000000.00 -6000000.00